| Assessment Status | NCPE Assessment Process Complete |
| HTA ID | 20060 |
| Drug | Atezolizumab in combination with bevacizumab |
| Brand | Tecentriq® |
| Indication | For the treatment of adult patients with advanced or unresectable hepatocellular carcinoma who have not received prior systemic therapy. |
| Assessment Process | |
| Rapid review commissioned | 21/12/2020 |
| Rapid review completed | 08/02/2021 |
| Rapid review outcome | A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of atezolizumab in combination with bevacizumab compared with the current standard of care. |
| Full pharmacoeconomic assessment commissioned by HSE | 24/02/2021 |
| Pre-submission consultation with Applicant | 22/11/2021 |
| Full submission received from Applicant | 26/07/2022 |
| Preliminary review sent to Applicant | 24/11/2022 |
| NCPE assessment re-commenced | 22/12/2022 |
| Factual accuracy sent to Applicant | 08/03/2023 |
| NCPE assessment re-commenced | 15/03/2023 |
| NCPE assessment completed | 08/05/2023 |
| NCPE assessment outcome | The NCPE recommends that atezolizumab (Tecentriq ®) in combination with bevacizumab not be considered for reimbursement unless cost-effectiveness can be improved relative to existing treatments*. |
*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.
